Reijm 2022 ¿ self-expandable duodenal metal stent placement for the palliation of gastric outlet obstruction over the past 20 years.Introduction duodenal stent placement is a palliative option for management of malignant gastric outlet obstruction (goo).In the last 20 years, management of gastrointestinal cancers has considerably changed.It is unknown if these changes have affected clinical outcome of duodenal stent placement.Duodenal stent placement: the median time between initial diagnosis and duodenal stent placement was 3.5 months in 1998¿2009 and 6 months in 2010¿2019 (p = (b)(4)).Duodenal stent placement was technically successful in (b)(4) of (b)(4) patients (b)(4); 1998¿2009 vs.2010¿2019, (b)(4) vs.(b)(4); p = (b)(4)).Reasons for unsuccessful stent placement were inability to pass the guidewire (n = 2), unspecified technical issues (n = 1), and a percutaneous transhepatic drain extending into the duodenum that prevented the stent from deploying (n = 1).Most patients were treated under conscious sedation (1998¿2009 vs.2010¿2019, (b)(4) vs.(b)(4);p = 0.01), but propofol sedation and general anesthesia were also used in the period 2010¿2019.The wallflex duodenal stent was the most frequently used stent in the period 1998¿2009 ((b)(4)), whereas the evolution duodenal stent was most frequently used in the period 2010¿ 2019 ((b)(4); p <(b)(4)) (table 2).A statistically significantly higher rate of duodenal stents overlapping the papilla was observed in the period 1998¿2009 ((b)(4) vs.(b)(4); p = (b)(4)).The percentage of patients who underwent drainage of the bile system prior to placement of the duodenal stent was comparable ((b)(4) vs.(b)(4); p = (b)(4)).Duodenal stent placement was performed under fluoroscopic guidance and according to standard procedures.During stent placement, patients were under conscious sedation, propofol sedation, or general anesthesia.Selection of the most appropriate stent design and length was based on the judgement and preference of the endoscopist.Biliary stent placement was performed before duodenal stent placement depending on biliary patency and stricture location.This complaint will capture 05x cases of stent migration (04x stent migration and 01x proximal part of stent turned to the bulbus wall, disabling food passage).All 05 cases resulted in the recurrence of patient symptoms (goo).
|
Device evaluation: the 05x evolution duodenal uncovered controlled released stent system devices of unknown rpn and lot number involved in this complaint were not available for evaluation.With the information provided, a document-based investigation was conducted.This file was created in response to the journal article ¿rejim 2022 - self-expandable duodenal metal stent placement for the palliation of gastric outlet obstruction over the past 20 years¿ to capture ¿04x stent migration and 01x proximal part of stent turned to the bulbus wall, disabling food passage¿.(b)(4) - reijm 2022 ¿ 1 death.(b)(4) - reijm ¿ multiple aes.(b)(4) - reijm 2022 ¿ fever & pressure necrosis.(b)(4) - reijm 2022 ¿ stent migration.(b)(4) - reijm 2022 ¿ stent obstruction caused by external compression.The device lab evaluation could not be completed as the device, or photographic evidence of the device, was not returned for evaluation.Note: as per table 2 of the literature article, evolution stent was used exclusively in the 2010-2019 group.No evolution stent was placed in the 1998-2009 group.Manufacturing records review: prior to distribution all devices are subjected to a visual inspection and functional inspection to ensure device integrity.Manufacturing records review could not be completed as the lot number is unknown.Historical data review: historical data was not reviewed as the lot number is unknown.Instructions for use and/label review: as per the ifu (ifu0053), stent misplacement and/or migration is a known potential adverse event associated with gi endoscopy "those associated with gi endoscopy include, but are not limited to: airway obstruction, allergic reaction to contrast to medication, aspiration, biliary obstruction, cardiac arrhythmia or arrest, cholangitis, fever, hemorrhage, hypotension, infection, perforation, reflux, respiratory depression or arrest.¿.¿additional complications include, but are not limited to: allergic reaction to nickel, bowel impaction, death (other than due to normal disease progression.), erosion of the luminal mucosa, foreign body sensation, inadequate expansion, intestinal perforation, nausea/vomiting, pain/discomfort, pancreatitis, pressure necrosis, septicemia, stent misplacement and/or migration, stent occlusion, tumour ingrowth or overgrowth, ulcerations.¿ there is no evidence to suggest that the customer did not follow the instructions for use or product label.Image review: an image was not returned for evaluation.Root cause analysis: a definitive root cause could not be determined from the available information.A possible root cause could be attributed to a procedural adverse event.As detailed above, stent misplacement and/or migration is a known adverse event as per the instructions for use.As per clinical input, there is a total of 05 cases of stent migration (04x stent migration and 01x proximal part of stent turned to the bulbus wall, disabling food passage [stent dysfunction]).Confirmation of complaint: complaint is confirmed based on customer and/or rep testimony.Confirmed quantity of 05x used devices.Summary of investigation: according to the initial reporter, the patient did experience an adverse effect due to this occurrence.As per table 1s from the literature article, all 04 cases of ¿stent migration¿, and the 01 case of ¿proximal part of patent stent turned to the bulbus wall.Disabling food passage¿ resulted in reoccurrence of patient symptoms (gastric outlet obstruction [goo]).Complaints of this nature will continue to be monitored for potential emerging trends.
|